Rubius Prepares Off-The-Shelf Red Cell Therapies For First Human Trial In 2018

Emerging Company Profile: Rubius Therapeutics is developing genetically engineered red blood cells and has raised $145m to take its first off-the-shelf, long-acting Red Cell Therapeutic into the clinic in 2018.